Class / Patent application number | Description | Number of patent applications / Date published |
514175000 | -C(=O)-O-is part of a hetero ring (e.g., lactone, etc.) | 25 |
20090088412 | COMPOSITION FOR TREATING CANCER CELLS AND PREPARATION METHOD THEREOF - A composition for treating cancer cells and a preparation method therefore is provided. The composition includes novel withanolide compounds derived from a Solanaceae plant, which the novel withanolide compounds have the cytotoxicity to the cancer cells. | 04-02-2009 |
20090306030 | Methods Of Inhibiting Osteoclast Activity - Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems. | 12-10-2009 |
20100249082 | MODULATORS OF HYPOXIA INDUCIBLE FACTOR-1 AND RELATED USES - The invention features compounds of formula (I): and pharmaceutically acceptable salts and prodrugs thereof, as well methods for modulating the effects of local and systemic hypoxic events using the compounds. | 09-30-2010 |
20100324004 | Method for Treating Diabetes - This application is directed to the use of steroid compounds for the selective inhibition of the enzyme PTP1B in a mammal for the treatment of diabetes. | 12-23-2010 |
20110178052 | 9-ALPHA ESTRATRIENE DERIVATIVES AS ER-BETA SELECTIVE LIGANDS FOR THE PREVENTION AND TREATMENT OF INTESTINAL CANCER - Use of 9α-estra-1,3,5(10)-triene derivatives of formula (I) | 07-21-2011 |
20110201584 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described. | 08-18-2011 |
20120077788 | USE OF TELOCINOBUFAGIN AS AN ANALGESIC IN THE TREATMENT OF ACUTE AND CHRONIC PAINS; PHARMACEUTICAL COMPOSITION CONTAINING TELOCINOBUFAGIN AND ITS USE - The present invention is directed to the use of telocinobufagin, or its pharmaceutically acceptable derivatives, in the manufacture of a medicament for the treatment or prevention of acute and chronic pains. The present invention also refers to a pharmaceutical composition comprising an effective amount of telocinobufagin; also provides a method to induce analgesia in response to acute and chronic pains that comprehends administering an effective amount of telocinobufagin to human beings or animals. According to the outcomes of in vivo assays, telocinobufagin is more potent than morphine, though without presenting the known side effects of opioids. In addition, in vivo and in vitro essays showed that TBC does not present cardiotoxicity. | 03-29-2012 |
20120108559 | RECEPTOR ACTIVATOR OF THE RANK RECEPTOR COMPLEX INHIBITOR - Methods and pharmaceutical compositions utilizing compounds of Formula II: for inhibiting osteoclastogenesis and the activity of osteoclasts in patients. | 05-03-2012 |
20120196842 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described. | 08-02-2012 |
20120252772 | Cucurbitane-Triterpenoid Compounds, Pharmaceutical Composition, Use and Preparation Method Thereof - Disclosed is a cucurbitane-triterpenoid compound for activating estrogen receptor activity, and a pharmaceutical composition, use and preparation method thereof. The cucurbitane-triterpenoid compound is presented as formula (I): | 10-04-2012 |
20130035321 | COMPOUNDS FOR THE TREATMENT OF OCULAR CANCER - In one aspect, the instant invention provides novel compounds and pharmaceutical compositions useful for treating proliferative diseases such as cancer. In another aspect, the invention provides methods of using certain compounds in the treatment of proliferative diseases such as cancer. In particular, the instant invention provides methods of treating ocular cancer (e.g., retinoblastoma) using intraarterial infusion to administer inventive compounds locally to the eye of a subject with an ocular cancer. | 02-07-2013 |
20130040921 | ANTICANCER STEROIDAL LACTONES UNSATURATED IN POSITION 7 (8) - A compound of general formula (I), wherein R | 02-14-2013 |
20130123224 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described. | 05-16-2013 |
20130143850 | METHODS AND COMPOSITIONS FOR STIMULATING REEPITHELIALISATION DURING WOUND HEALING - The present invention relates to methods and compositions for stimulating reepithelialisation during wound healing. More particularly, the present invention relates to a mmeralocorticoid receptor antagonist or an inhibitor of mineralocorticoid receptor gene expression for use in a method for stimulating reepithelialisation of the skin or of the cornea during wound healing. | 06-06-2013 |
20130345186 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described. | 12-26-2013 |
20140088056 | CARDIAC GLYCOSIDES ARE POTENT INHIBITORS OF INTERFERON-BETA GENE EXPRESSION - The invention provides for a method of inhibiting interferon-beta gene expression and/or reducing the level of interferon-beta in a cell by contacting the cell with a Na | 03-27-2014 |
20140128356 | Na/K-ATPase Ligand - Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described. | 05-08-2014 |
20140221327 | Method of Diagnosing and Therapeutically Treating a Patient for a Traumatic Brain Injury - Known or suspected traumatic brain injuries may be treated therapeutically by administering a therapeutically effective dose of resibufogenin. A preferred method for determining if a patient has a traumatic brain injury includes obtaining a body specimen from the patient, determining the concentration of marinobufagenin in the body specimen, comparing the concentration of marinobufagenin to the concentration in such body specimens in normal patients, and if the marinobufagenin concentration is substantially above the concentration of a normal patient, concluding traumatic brain injury exists. In a preferred embodiment, a substantial elevation is deemed to be an increase of about 30 percent above the marinobufagenin concentration of a normal patient. The body specimen may be blood, urine, or cerebrospinal fluid. If a substantial elevation is deemed to exist, the magnitude of the departure from the concentration of a normal patient may be employed in determining the timing and nature of treatment provided to the patient. The method may be repeated at predetermined intervals to monitor changes in the marinobufagenin with time. | 08-07-2014 |
20140256694 | STEROID ANTIBIOTIC CONJUGATES - The present invention describes steroid antibiotic conjugates. These single drug entities are formed connecting a steroid moiety and two same antibiotics moieties, or a steroid moiety and two different antibiotics moieties. Upon topical application to the eye, the conjugate hybrid would undergo enzymatic and/or hydrolytic cleavage to release the individual drugs. | 09-11-2014 |
20140357608 | TACCALONOLIDE MICROTUBULE STABILIZERS - The invention provides epoxytaccalonolide microtubule stabilizers and their use as anti-proliferative microtubule stabilizing agents. | 12-04-2014 |
20150320771 | INDOLEALKYLAMINO-WITHASTEROID CONJUGATES AND METHOD OF USE - A group of indolealkylamino-withasteroid conjugates, isolated and purified from | 11-12-2015 |
20150338397 | Use of Bufodienolides in Diagnosing and Treating Essential Hypertension - Certain embodiments are directed to methods of identifying patients with essential by detecting elevated levels of marinobufagenin (MBG) and treating the same with anti-MBG agents. | 11-26-2015 |
20150342966 | Na/K-ATPase Ligand and Uses Thereof in Wound Healing - Methods and compositions for detecting, treating, characterizing, and diagnosing interstitial lung and/or fibrotic diseases are described. | 12-03-2015 |
20160039865 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS - Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described. | 02-11-2016 |
20160120881 | USE OF BUFODIENOLIDES IN DIAGNOSING AND TREATING ESSENTIAL HYPERTENSION - Certain embodiments are directed to methods of identifying patients with essential hypertension by detecting elevated levels of marinobufagenin (MBG) and treating the same with anti-MBG agents. | 05-05-2016 |